American Heart Journal
Volume 154, Issue 3 , Pages 448-453 , September 2007

Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study

  • Omid Salehian, MSc, MD, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • Corresponding Author InformationReprint requests: Omid Salehian, MSc, MD, FACC, McMaster University Medical Center, 1200 Main Street West, Room 3U8, Hamilton, Ontario, Canada L8N 3Z5.
    • ,
  • Jeff Healey, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Bruce Stambler, MD

      Affiliations

    • University Hospitals of Cleveland, Cleveland, OH
    • ,
  • Khalid Alnemer, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Khalid Almerri, MD

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • ,
  • John Grover, MD

      Affiliations

    • St Vincent Hospital, Portland, OR
    • ,
  • Iqbal Bata, MD

      Affiliations

    • Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
    • ,
  • Johannes Mann, MD

      Affiliations

    • Schwabing Clinical Centre, Ludwig Maximilians University, Munich, Germany
    • ,
  • James Matthew, MD

      Affiliations

    • University of Iowa College of Medicine, Iowa City, Iowa
    • Wisconsin Cardiovascular Group, Milwaukee, WI
    • ,
  • Janice Pogue, PhD

      Affiliations

    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Salim Yusuf, MBBS, DPhil, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Gilles Dagenais, MD, MSc, FACC

      Affiliations

    • Laval University Heart and Lung Institute, Quebec City, Quebec, Canada
    • ,
  • Eva Lonn, MD, MSc, FACC

      Affiliations

    • Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
    • Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
    • ,
  • On Behalf of the HOPE Investigators

Received 27 February 2007 ,Accepted 8 April 2007.

References 

  1. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840–844
  2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988
  3. Nattel S, Li D. Ionic remodeling in the heart: pathophysiological significance and new therapeutic opportunities for atrial fibrillation. Circ Res. 2000;87:440–447
  4. Li D, Shinagawa K, Pang L, et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation. 2001;104:2608–2614
  5. Shinagawa K, Mitamura H, Ogawa S, et al. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling. Cardiovasc Res. 2002;54:438–446
  6. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000;101:2612–2617
  7. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376–380
  8. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926–2931
  9. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712–719
  10. Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151:985–991
  11. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  12. The Hope Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol. 1996;12:127–137
  13. Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings. Standards and procedures for measurement and classification. Boston: John Wright PSG Inc.; 1982;
  14. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting–enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353:611–616
  15. van den Berg MP, Crijns HJ, van Veldhuisen DJ, et al. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1:355–363
  16. Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86:527–532
  17. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090–2098
  18. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354:1751–1756
  19. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331–336
  20. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting–enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772–776
  21. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548–557
  22. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–1839
  23. Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol. 2003;41:2197–2204
  24. Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol. 2003;42:1785–1792
  25. Boldt A, Scholl A, Garbade J, et al. ACE-inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation. Basic Res Cardiol. 2006;101:261–267
  26. Marin F, Pascual DA, Roldan V, et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol. 2006;97:55–60
  27. Shiroshita-Takeshita A, Schram G, Lavoie J, et al. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313–2319
  28. Teo K, Yusuf S, Sleight P, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61

PII: S0002-8703(07)00425-5

doi: 10.1016/j.ahj.2007.04.062

American Heart Journal
Volume 154, Issue 3 , Pages 448-453 , September 2007

Article Tools

* Image Usage & Resolution